Screening for HIV: Recommendation statement

American Family Physician

Volumn 72, Issue 11, 2005, Pages 2287-2298

  Calonge, Ned ^a  

^a AGENCY FOR HEALTHCARE RESEARCH AND QUALITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ;

BREAST FEEDING; CARDIOVASCULAR RISK; CESAREAN SECTION; CLINICAL PROTOCOL; CLINICAL TRIAL; DIABETES MELLITUS; DIAGNOSTIC TEST; EVIDENCE BASED MEDICINE; FOOD AND DRUG ADMINISTRATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; INFECTION RATE; INFECTION RISK; MASS SCREENING; METABOLIC DISORDER; MORTALITY; PREGNANCY; REVIEW; VERTICAL TRANSMISSION; VIRUS DETECTION; VIRUS VIRULENCE;

ADOLESCENT; ADULT; COUNSELING; EVIDENCE-BASED MEDICINE; FEMALE; HIV INFECTIONS; HUMANS; MALE; MASS SCREENING; RISK FACTORS; UNITED STATES;

EID: 28744455645     PISSN: 0002838X     EISSN: 0002838X     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. U.S. Preventive Services Task Force. Guide to Clinical Preventive Services. 2nd ed. Washington, DC: Office of Disease Prevention and Health Promotion; 1996
2. Harris RP, Helfand M, Woolf SH, et al; Methods Work Group, Third U.S. Preventive Services Task Force. Current methods of the U.S. Preventive Services Task Force: a review of the process. Am J Prev Med. 2001;20(3S):21-35.
3. Centers for Disease Control and Prevention. Cases of HIV Infection and Aids in the United States, 2002. HIV/AIDS Surveillance Report, Vol. 14. Accessed at http://www.cdc.gov/hiv/stats/hasr1402.htm on 23 March 2005.
4. Fleming P, Byers RH, Sweeney PA, Daniels D, Karon JM, Janssen RS. HIV prevalence in the United States, 2000. In: Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections. Seattle, Washington; February 24-28, 2002. Alexandria, Virginia: Foundation for Retrovirology and Human Health.
5. Kochanek KD, Smith BL. Deaths: Preliminary Data for 2002. National vital statistics reports; vol. 52, no. 13. Hyattsville, MD: National Center for Health Statistics; 2004.
6. Centers for Disease Control and Prevention. Increases in HIV diagnoses - 29 states, 1999-2002. MMWR Morb Mortal Wkly Rep. 2003;52(47):1145-8.
7. Lee LM, Fleming PL. Trends in human immunodeficiency virus diagnoses among women in the United States, 1994-1998. J Am Med Womens Assoc. 2001;56(3):94-9.
8. Bulterys M, Nolan ML, Jamieson DJ, Dominguez K, Fowler MG. Advances in the prevention of mother-to-child HIV-1 transmission: current issues, future challenges. AIDScience. 2002;2(4).
9. Office of the Inspector General. Reducing obstetrician barriers to offering HIV testing. Washington, DC: Department of Health and Human Services; 2002. Accessed at www.aidscience.org/articles/aidscience017.asp on 12 March 2005.
10. Centers for Disease Control and Prevention. Update: serologic testing for HIV-1 antibody-United States, 1988 and 1989. MMWR Morb Mortal Wkly Rep. 1990;39(22):380-3.
11. Kleinman S, Busch MP, Hall L, et al. Falsepositive HIV-1 test results in a low-risk screening setting of voluntary blood donation. Retrovirus Epidemiology Donor Study. JAMA. 1998;280(12):1080-5.
12. Celum CL, Coombs RW, Jones M, et al. Risk factors for repeatedly reactive HIV-1 EIA and indeterminate Western blots. Arch Intern Med. 1994;154:1129-37.
13. Butlerys M, Jamieson DJ, O'Sullivan MJ, et al. Rapid HIV-1 testing during labor: a multicenter study. JAMA. 2004;292(2):219-23.
14. O'Connell RJ, Merrit TM, Malia JA, et al. Performance of the OraQuick rapid antibody test for diagnosis of human immunodeficiency virus type 1 infection in patients with various levels of exposure to highly active antiretroviral therapy. J Clin Microbiol. 2003;41(5);2153-5.
15. Reynolds SJ, Ndongala LM, Luo CC, et al. Evaluation of a rapid test for the detection of antibodies to human immunodeficiency virus type 1 and 2 in the setting of multiple transmitted viral subtypes. Int J STD AIDS. 2002;13(3):171-3.
16. Gallo D, George JF, Fitchen JH, Goldstein AS, Hindahl MS. Evaluation of a system using oral mucosal transudate for HIV-1 antibody screening and confirmatory testing. OrasSure HIV Clinical Trials Group. JAMA. 1997;277(3):254-8.
17. Martinez PM, Torres AR, de Lejarazu R, et al. Human immunodeficiency virus antibody testing by enzyme-linked fluorescent and Western blot assays using serum, gingival-crevicular transudate, and urine samples. J Clin Microbiol. 1999;37:1100-6.
18. Frank AP, Wandell MG, Headings MD, et al. Anonymous HIV testing using home collection and telemedicine counseling. A multicenter evaluation. Arch Intern Med. 1997:l157(3):309-14.
19. Peterman TA, Todd KA, Mupanduki I. Opportunities for targeting publicly funded human immunodeficiency virus counseling and testing. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;12(1):69-74.
20. Klein D, Hurley LB, Merrill D, Quescenberry CP, Jr. Review of medical encounters in the 5 years before a diagnosis of HIV-1 infection: implications for early detection. J Acquir Immune Defic Syndr. 2003;32:143-52.
21. Centers for Disease Control and Prevention. Voluntary HIV testing as part of routine medical care-Massachusetts, 2002. MMWR Morb Mortal Wkly Rep. 2004;53(24):523-6.
22. Centers for Disease Control and Prevention. Routinely recommended HIV testing at an urban urgent-care clinic-Atlanta, Georgia, 2000. MMWR Morb Mortal Wkly Rep. 2001;50(25):538-41.
23. Walensky RP, Losina E, Steger-Craven KA, Freedberg KA. Identifying undiagnosed human immunodeficiency virus: the yield of routine, voluntary inpatient testing. Arch Intern Med. 2002;162(8):887-92.
24. Paltiel AD, Weinstein MC, Kimmel AD, et al. Expanded screening for HIV in the United States-an analysis of cost-effectiveness. N Engl J Med. 2005;352:586-95.
25. Sanders GD, Bayoumis AM, Sundaram V, et al. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. N Engl J Med. 2005;352:570-85.
26. McNaghten AD, Hanson DL, Jones JL, Dworkin MS, Ward JW. Effects of antiretroviral therapy and opportunistic illness primary chemoprophylaxis on survival after AIDS diagnosis. Adult/Adolescent Spectrum of Disease Group. AIDS. 1999;13(13):1687-95.
27. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338(13):853-60.
28. Dybul M, Bolan R, Condoluci D, et al. Evaluation of initial CD4+ T cell counts in individuals with newly diagnoses human immunodeficiency virus infection, by sex and race, in urban settings. J Infect Dis. 2002;185:1818-21.
29. Ioannidis JP, Cappelleri JC, Skolnik PR, Lau J, Sacks HS. A meta-analysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens. Arch Intern Med. 1996;156(2):177-88.
30. Bucher HC, Griffith L, Guyatt GH, Opravil M. Meta-analysis of prophylactic treatments against Pneumocystic carinii pneumonia and toxoplasma encephalitis in HIV-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;15(2):104-14.
31. Centers for Disease Control and Prevention. Recommendations for use of antiretroviral drugs in pregnant HIV-1 infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. Accessed at http://aidsinfo.nih.gov/guidelines/perinatal/PER_062304.pdf on 23 March 2005.
32. The European Mode of Delivery Collaboration. Elective caesarean-section versus vaginal delivery in prevention of vertical HIV-1 transmission: a randomised clinical trial. Lancet. 1999;353(9158):1035-9.
33. Gielen AC, O'Campo P, Faden RR, Eke A. Women's disclosure of HIV status: experiences of mistreatment and violence in an urban setting. Women Health. 1997;25(3):19-31.
34. Centers for Disease Control and Prevention. Adoption of protective behaviors among persons with recent HIV infection and diagnosis-Alabama, New Jersey, and Tennessee, 1997-1998. MMWR Morb Mortal Wkly Rep. 2000;49:512-5.
35. Crepaz N, Hart TA, Marks G. Highly active antiretroviral therapy and sexual risk behavior: a meta-analytic review. JAMA. 2004;292:224-36.
36. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. October 29, 2004. Accessed at http://aidsinfo.nih.gov/guidelines/adult/AA_102904.pdf on 29 October 2004.
37. Friis-Moller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349(21):1993-2003.
38. Tuomala RE, Shapiro DE, Mofenson LM, et al. Antiretroviral therapy during pregnancy and the risk of an adverse outcome. N Engl J Med. 2002;346(24):1863-70.
39. Centers for Disease Control and Prevention. Revised guidelines for HIV counseling, testing, and referral and revised recommendations for HIV screening of pregnant women. MMWR Morb Mortal Wkly Rep. 2001;50(19):1-86.
40. Periodic health examination, 1992 update: 3. HIV antibody screening. Canadian Task Force on the Periodic Health Examination. CMAJ. 1992;147(6):867-76.
41. American Medical Association. Universal, routine screening of pregnant women for HIV infection. Accssed at http://www.amaassn.org/ama/pub/category/ 13548.html on 23 March 2005.
42. American Academy of Family Physicians. HIV Infection Statements and Policies. Accessed at http://www.aafp.org/x1586.xml on 23 March 2005.
43. ACOG committee opinion number 304, November 2004. Prenatal and perinatal human immunodeficiency virus testing: expanded recommendations. Obstet Gynecol. 2004;104:1119-24.
44. American College of Physicians and Infectious Diseases Society of America. Human immunodeficiency virus (HIV) infection. Ann Intern Med. 1994;120:310-9.
45. Aberg JA, Gallant JE, Anderson J, et al. Primary care guidelines for the management of persons infected with human immunodeficiency virus: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2004;39(5):609-29.
46. Committee on Pediatric AIDS and Committee on Adolescents. Adolescents and human immunodeficiency virus: the role of the pediatrician in prevention and intervention. Pediatrics. 2001;107:188-90.
47. Human immunodeficiency virus screening. Joint statement of the American Academy of Pediatrics and the American College of Obstetricians and Gynecologists. Pediatrics. 1999;104(1 Pt 1):128.
48. American College of Nurse-Midwives. Position statement: Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome (AIDS). 2003. Accessed at http://www.midwife.org/prof/display.cfm?id=403 on 24 March 2005.
49. Chou R, Huffman LH, Fu R, Smits AK, Korthuis PT. Screening for human immunodeficiency virus: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2005;143:55-73.
50. Chou R, Smits AK, Huffman LH, Fu R, Korthuis PT. Prenatal screening for human immunodeficiency virus: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2005;143:38-54.
51. Chou R, Korthuis PT, Huffman LH, Smits AK. Screening for Human Immunodeficiency Virus in Adolescents and Adults. Evidence Synthesis No. 38. (Prepared by the Oregon Evidence-based Practice Center under Contract No. 290-02-0024). Rockville, MD: Agency for Healthcare Research and Quality. July 2005. (Available on the AHRQ Web site at: http://www.ahrq.gov/clinic/serfiles. htm)
52. Chou R, Smits AK, Huffman LH, Korthuis PT. Screening for Human Immunodeficiency Virus in Pregnant Women. Evidence Synthesis No. 39. (Prepared by the Oregon Evidence-based Practice Center under Contract No. 290-02-0024). Rockville, MD: Agency for Healthcare Research and Quality. July 2005. (Available on the AHRQ Web site at: http://www.ahrq.gov/clinic/serfiles.htm)